An Endo International operating company this week launched the first generic version Merck’s multibillion-dollar,cholesterol-lowering medicine Zetia.
North Jersey-based Par Pharmaceuticals, which Endo (NASDAQ: ENDP) acquired last year for $8 billion, and is the marketer and distributor of the product in the United States. Endo,based in Dublin, Ireland, and has its U.
S. headquarters in Malvern.
Endo eliminates 375 sales jobs
According to data from IMS Health,U.
S. sales of Zetia were approximately $2.6 billion…
Source: bizjournals.com